Metabolic

GLP-2 TZ

Dual-Incretin Metabolic Compound - Dual GIP/GLP-1 receptor co-agonist studied in glucose-handling and energy-balance research.

GLP-2 TZ is a dual-incretin research peptide that engages both the GIP and GLP-1 receptors - the two-receptor strategy studied for combined effects on glucose handling, insulin signaling and energy-balance regulation.

The property most often cited in the literature is that it is GIP-forward - relatively more potent at the GIP receptor than at GLP-1 - so it tends to be used as a comparator when separating GIP-driven from GLP-1-driven effects rather than as a general incretin control. Receptor-selectivity panels report the two potencies separately for that reason.

GLP-2 TZ specifications

Molecular weight

4813.45 g/mol

Sequence

GIP / GLP-1 dual receptor agonist peptide

Residues

39-residue acylated dual-agonist peptide

Presentation

Lyophilized powder

Documented purity

99.60% by HPLC

Available sizes

10mg ($55), 30mg ($90), 60mg ($150), 100mg ($220)

Archived COA lots

14

Intended use

Laboratory research use only. Not for human or veterinary use.

Studied pathways

• Dual incretin signaling - Studied for simultaneous GIP- and GLP-1-receptor activity in glucose-handling and energy-balance models.

Reported mechanisms in the literature

• Primary incretin axis - Engages the GIP receptor with near-native affinity - the GIP-forward half of the dual-agonist profile studied for insulin signaling and energy handling. (Willard et al.)
• Co-agonist axis - Simultaneously engages the GLP-1 receptor, combining two incretin signals in one molecule for amplified glucose- and appetite-pathway activity. (Frías et al.)

What GLP-2 TZ is researched for

• Energy-balance regulation - Studied as a dual GIP/GLP-1 co-agonist for glucose-handling and energy-balance endpoints in metabolic research. (Published metabolic literature)
• Glucose handling - Investigated for combined GIP- and GLP-1-receptor activity on insulin signaling and glucose-handling endpoints. (Frías et al.)

GLP-2 TZ certificates of analysis on file

Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.

GLP-2 TZ sizes and pricing

Size	Price	Per mg
10mg	$55	$5.50 per mg
30mg	$90	$3.00 per mg
60mg	$150	$2.50 per mg
100mg	$220	$2.20 per mg

Published literature on GLP-2 TZ

The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.

Research notes

Research notes: GLP-2 TZ

Background

GLP-2 TZ is a long, fatty-acid-modified peptide (about 4,813 g/mol, 39 residues) studied as a dual agonist of the GIP and GLP-1 receptors. Despite "GLP-2" in the catalog name, it is not a GLP-2 receptor agonist; the two receptors under study are GIP and GLP-1. Receptor-pharmacology work on this class describes it as imbalanced, with more potency at the GIP receptor than at the GLP-1 receptor, and biased in how it signals at the GLP-1 receptor (Willard et al., 2020). Discovery-to-proof-of-concept and clinical development are reviewed by Coskun et al. (2018) and Frias et al. (2018). Because the GIP arm dominates, the class is often used to separate GIP-driven from GLP-1-driven effects in glucose, insulin-signaling and energy-balance models.

What the Aspect certificates show

There are 13 certificate records across four vial sizes (10mg, 30mg, 60mg, 100mg), all from Freedom Diagnostics, dated 11 March 2026 to 18 September 2026. Reported HPLC purity runs from 99.61% to 99.99%. Identity is confirmed by LC-MS/MS, and the appearance is reported as white lyophilized powder. Two of the records print no lot number on the report; the certificate table shows "See certificate" for those. Each full report is available as a PDF on this page and in the COA library.

How it differs from related compounds

GLP-3 RT adds a third receptor (glucagon) to the incretin pair, so comparing the two separates a two-receptor from a three-receptor profile. 5-Amino-1MQ is a metabolic comparator with an unrelated mechanism: it inhibits an enzyme rather than binding a receptor.

Citations

Willard FS et al., JCI Insight 2020 (PMID 32730231). Coskun T et al., Mol Metab 2018 (PMID 30473097). Frias JP et al., Lancet 2018 (PMID 30293770).

Third-party publications are cited for context and are not Aspect Peptides claims. For laboratory research use only.

GLP-2 TZ frequently asked questions

Documented to 99.60% purity by HPLC · third-party COA every lot · from $55 · For laboratory research use only.

Related Metabolic compounds

• GLP-1 S - Single-agonist GLP-1 research compound.
• GLP-3 RT - Triple-receptor GLP research compound (GLP-1/GIP/glucagon class).
• Cagrilintide - Acylated amylin analogue studied for amylin and calcitonin receptor signaling.
• GLP-3 RT + Cagri - GLP-3 RT (10mg) co-formulated with Cagrilintide (2mg) in one vial.
• 5-Amino-1MQ - Small-molecule NNMT inhibitor studied in metabolism research.
• MOTS-c - Mitochondrial-derived peptide studied for metabolic regulation.